Research diagnostic criteria for mild cognitive impairment with Lewy bodies: a systematic review and meta-analysis

Paul C. Donaghy; Claudia Carrarini; Daniel Ferreira; Annegret Habich; Dag Aarsland; Claudio Babiloni; Ece Bayram; Joseph P. M. Kane; Simon J. G. Lewis; Andrea Pilotto; Alan J. Thomas; Laura Bonanni; Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Lewy Body Dementias Prodromal Working Group

doi:10.1002/alz.13105

Research diagnostic criteria for mild cognitive impairment with Lewy bodies: a systematic review and meta-analysis

Paul C. Donaghy^*, Claudia Carrarini, Daniel Ferreira, Annegret Habich, Dag Aarsland, Claudio Babiloni, Ece Bayram, Joseph P. M. Kane, Simon J. G. Lewis, Andrea Pilotto, Alan J. Thomas, Laura Bonanni, Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Lewy Body Dementias Prodromal Working Group

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

27 Citations (Scopus)

43 Downloads (Pure)

Abstract

Introduction: Operationalized research criteria for mild cognitive impairment with Lewy bodies (MCI-LB) were published in 2020. The aim of this systematic review and meta-analysis was to review the evidence for the diagnostic clinical features and biomarkers in MCI-LB set out in the criteria. Methods: MEDLINE, PubMed, and Embase were searched on 9/28/22 for relevant articles. Articles were included if they presented original data reporting the rates of diagnostic features in MCI-LB. Results: Fifty-seven articles were included. The meta-analysis supported the inclusion of the current clinical features in the diagnostic criteria. Evidence for striatal dopaminergic imaging and meta-iodobenzylguanidine cardiac scintigraphy, though limited, supports their inclusion. Quantitative electroencephalogram (EEG) and fluorodeoxyglucose positron emission tomography (PET) show promise as diagnostic biomarkers. Discussion: The available evidence largely supports the current diagnostic criteria for MCI-LB. Further evidence will help refine the diagnostic criteria and understand how best to apply them in clinical practice and research. Highlights: A meta-analysis of the diagnostic features of MCI-LB was carried out. The four core clinical features were more common in MCI-LB than MCI-AD/stable MCI. Neuropsychiatric and autonomic features were also more common in MCI-LB. More evidence is needed for the proposed biomarkers. FDG-PET and quantitative EEG show promise as diagnostic biomarkers in MCI-LB.

Original language	English
Pages (from-to)	3186-3202
Number of pages	17
Journal	Alzheimer's and Dementia
Volume	19
Issue number	7
DOIs	https://doi.org/10.1002/alz.13105
Publication status	Published - Jul 2023
Externally published	Yes

Bibliographical note

Copyright the Author(s) 2023. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

biomarkers
dementia with Lewy bodies
diagnosis
diagnostic criteria
electroencephalography
imaging
Lewy body disease
mild cognitive impairment
symptoms

Access to Document

10.1002/alz.13105Licence: CC BY

Publisher version (open access)Final published version, 373 KBLicence: CC BY

Cite this

Donaghy, P. C., Carrarini, C., Ferreira, D., Habich, A., Aarsland, D., Babiloni, C., Bayram, E., Kane, J. P. M., Lewis, S. J. G., Pilotto, A., Thomas, A. J., Bonanni, L., & Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Lewy Body Dementias Prodromal Working Group (2023). Research diagnostic criteria for mild cognitive impairment with Lewy bodies: a systematic review and meta-analysis. Alzheimer's and Dementia, 19(7), 3186-3202. https://doi.org/10.1002/alz.13105

@article{f15d8d23add94127b51bc0e3701fd423,

title = "Research diagnostic criteria for mild cognitive impairment with Lewy bodies: a systematic review and meta-analysis",

abstract = "Introduction: Operationalized research criteria for mild cognitive impairment with Lewy bodies (MCI-LB) were published in 2020. The aim of this systematic review and meta-analysis was to review the evidence for the diagnostic clinical features and biomarkers in MCI-LB set out in the criteria. Methods: MEDLINE, PubMed, and Embase were searched on 9/28/22 for relevant articles. Articles were included if they presented original data reporting the rates of diagnostic features in MCI-LB. Results: Fifty-seven articles were included. The meta-analysis supported the inclusion of the current clinical features in the diagnostic criteria. Evidence for striatal dopaminergic imaging and meta-iodobenzylguanidine cardiac scintigraphy, though limited, supports their inclusion. Quantitative electroencephalogram (EEG) and fluorodeoxyglucose positron emission tomography (PET) show promise as diagnostic biomarkers. Discussion: The available evidence largely supports the current diagnostic criteria for MCI-LB. Further evidence will help refine the diagnostic criteria and understand how best to apply them in clinical practice and research. Highlights: A meta-analysis of the diagnostic features of MCI-LB was carried out. The four core clinical features were more common in MCI-LB than MCI-AD/stable MCI. Neuropsychiatric and autonomic features were also more common in MCI-LB. More evidence is needed for the proposed biomarkers. FDG-PET and quantitative EEG show promise as diagnostic biomarkers in MCI-LB.",

keywords = "biomarkers, dementia with Lewy bodies, diagnosis, diagnostic criteria, electroencephalography, imaging, Lewy body disease, mild cognitive impairment, symptoms",

author = "Donaghy, {Paul C.} and Claudia Carrarini and Daniel Ferreira and Annegret Habich and Dag Aarsland and Claudio Babiloni and Ece Bayram and Kane, {Joseph P. M.} and Lewis, {Simon J. G.} and Andrea Pilotto and Thomas, {Alan J.} and Laura Bonanni and {Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Lewy Body Dementias Prodromal Working Group}",

note = "Copyright the Author(s) 2023. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",

year = "2023",

month = jul,

doi = "10.1002/alz.13105",

language = "English",

volume = "19",

pages = "3186--3202",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Wiley-Blackwell, Wiley",

number = "7",

}

Donaghy, PC, Carrarini, C, Ferreira, D, Habich, A, Aarsland, D, Babiloni, C, Bayram, E, Kane, JPM, Lewis, SJG, Pilotto, A, Thomas, AJ, Bonanni, L & Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Lewy Body Dementias Prodromal Working Group 2023, 'Research diagnostic criteria for mild cognitive impairment with Lewy bodies: a systematic review and meta-analysis', Alzheimer's and Dementia, vol. 19, no. 7, pp. 3186-3202. https://doi.org/10.1002/alz.13105

TY - JOUR

T1 - Research diagnostic criteria for mild cognitive impairment with Lewy bodies

T2 - a systematic review and meta-analysis

AU - Donaghy, Paul C.

AU - Carrarini, Claudia

AU - Ferreira, Daniel

AU - Habich, Annegret

AU - Aarsland, Dag

AU - Babiloni, Claudio

AU - Bayram, Ece

AU - Kane, Joseph P. M.

AU - Lewis, Simon J. G.

AU - Pilotto, Andrea

AU - Thomas, Alan J.

AU - Bonanni, Laura

AU - Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment Lewy Body Dementias Prodromal Working Group

N1 - Copyright the Author(s) 2023. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2023/7

Y1 - 2023/7

N2 - Introduction: Operationalized research criteria for mild cognitive impairment with Lewy bodies (MCI-LB) were published in 2020. The aim of this systematic review and meta-analysis was to review the evidence for the diagnostic clinical features and biomarkers in MCI-LB set out in the criteria. Methods: MEDLINE, PubMed, and Embase were searched on 9/28/22 for relevant articles. Articles were included if they presented original data reporting the rates of diagnostic features in MCI-LB. Results: Fifty-seven articles were included. The meta-analysis supported the inclusion of the current clinical features in the diagnostic criteria. Evidence for striatal dopaminergic imaging and meta-iodobenzylguanidine cardiac scintigraphy, though limited, supports their inclusion. Quantitative electroencephalogram (EEG) and fluorodeoxyglucose positron emission tomography (PET) show promise as diagnostic biomarkers. Discussion: The available evidence largely supports the current diagnostic criteria for MCI-LB. Further evidence will help refine the diagnostic criteria and understand how best to apply them in clinical practice and research. Highlights: A meta-analysis of the diagnostic features of MCI-LB was carried out. The four core clinical features were more common in MCI-LB than MCI-AD/stable MCI. Neuropsychiatric and autonomic features were also more common in MCI-LB. More evidence is needed for the proposed biomarkers. FDG-PET and quantitative EEG show promise as diagnostic biomarkers in MCI-LB.

AB - Introduction: Operationalized research criteria for mild cognitive impairment with Lewy bodies (MCI-LB) were published in 2020. The aim of this systematic review and meta-analysis was to review the evidence for the diagnostic clinical features and biomarkers in MCI-LB set out in the criteria. Methods: MEDLINE, PubMed, and Embase were searched on 9/28/22 for relevant articles. Articles were included if they presented original data reporting the rates of diagnostic features in MCI-LB. Results: Fifty-seven articles were included. The meta-analysis supported the inclusion of the current clinical features in the diagnostic criteria. Evidence for striatal dopaminergic imaging and meta-iodobenzylguanidine cardiac scintigraphy, though limited, supports their inclusion. Quantitative electroencephalogram (EEG) and fluorodeoxyglucose positron emission tomography (PET) show promise as diagnostic biomarkers. Discussion: The available evidence largely supports the current diagnostic criteria for MCI-LB. Further evidence will help refine the diagnostic criteria and understand how best to apply them in clinical practice and research. Highlights: A meta-analysis of the diagnostic features of MCI-LB was carried out. The four core clinical features were more common in MCI-LB than MCI-AD/stable MCI. Neuropsychiatric and autonomic features were also more common in MCI-LB. More evidence is needed for the proposed biomarkers. FDG-PET and quantitative EEG show promise as diagnostic biomarkers in MCI-LB.

KW - biomarkers

KW - dementia with Lewy bodies

KW - diagnosis

KW - diagnostic criteria

KW - electroencephalography

KW - imaging

KW - Lewy body disease

KW - mild cognitive impairment

KW - symptoms

UR - http://www.scopus.com/inward/record.url?scp=85153756392&partnerID=8YFLogxK

U2 - 10.1002/alz.13105

DO - 10.1002/alz.13105

M3 - Review article

C2 - 37096339

AN - SCOPUS:85153756392

SN - 1552-5260

VL - 19

SP - 3186

EP - 3202

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 7

ER -

Research diagnostic criteria for mild cognitive impairment with Lewy bodies: a systematic review and meta-analysis

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this